Helen Davis

Curative Biotechnology secures a key U.S. patent for a metformin eye-drop, a novel approach that could transform treatment for macular degeneration.

Slate Medicines appoints Mark W. Hahn, a CFO known for steering biotechs to massive acquisitions, signaling a major strategic push for its next-gen therapy.

As home care agencies face a perfect storm of financial cuts and regulatory burdens, technology firms like Axxess are betting that AI is the key to survival.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

An award for an AI search tool seems routine, but Ask Ella signals a deeper rewiring of the life sciences industry, turning data drudgery into strategic speed.

ProQR's Axiomer platform achieves its first human validation, showing promise for rare pediatric liver diseases and signaling a major step for RNA editing.

Amity University and L&T Technology Services launch a Centre of Excellence to bridge India's critical EV skills gap, creating a new pipeline for innovation.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

Takeda is deploying Boltz's frontier AI across its labs, betting that AI agents can accelerate medicine by acting as a creative partner for scientists.

Iceland's Alvotech secured a crucial capital infusion. It's a high-stakes play to survive financial pressures and compete in the next wave of affordable medicine.

A new partnership aims to replace needles with pills for a powerful class of drugs, using advanced AI to solve a multi-billion dollar challenge in medicine.

The first delivery of HII's new REMUS 130 UUV to a U.S. ally marks a shift in undersea warfare, offering affordable, adaptable tech to counter new threats.

As Southeast Asia races to become an EV powerhouse, the real challenge lies on the factory floor. A new wave of traceable assembly tech aims to solve it.

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.

How a Swedish city's new aquatic center, powered by unique CO₂ technology, reveals a future where public infrastructure can be both sustainable and strategic.

Blue Cross MA's new partnership with Thyme Care moves beyond paying for procedures, betting on a value-based model to guide patients and curb spiraling costs.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

As NEXGEL prepares for a key investor conference, it faces a crucial test: convincing the market its advanced hydrogel tech can overcome recent financial hurdles.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?